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The serine-threonine kinase, Akt, inhibits cardiomyo-
cyte apoptosis acutely both in vitro and in vivo. How-
ever, the effects of chronic Akt activation in the heart
are unknown. To address this issue, we generated trans-
genic mice (TG) with cardiac-specific expression of a
constitutively active mutant of Akt (myr-Akt) driven by
the myosin heavy chain- promoter. Three TG
founders (9–19 weeks) died suddenly with massive car-
diac dilatation. Two viable TG lines (TG564 and TG20)
derived from independent founders demonstrated car-
diac-specific transgene expression as well as activation
of Akt and p70S6 kinase. TG564 (n  19) showed cardiac
hypertrophy with a heart/body weight ratio 2.3-fold
greater than littermates (n 17, p < 0.005). TG20 (n 18)
had less marked cardiac hypertrophy with a heart/body
weight ratio 1.6-fold greater than littermates (n 17, p <
0.005). Isolated TG564 myocytes were also hypertrophic
with surface areas 1.7-fold greater than littermates (p <
0.000001). Echocardiograms in both lines demonstrated
concentric hypertrophy and preserved systolic func-
tion. After ischemia-reperfusion, TG had a 50% reduc-
tion in infarct size versus TG (17  3% versus 34  4%,
p < 0.001). Thus, chronic Akt activation is sufficient to
cause a spectrum of phenotypes from moderate cardiac
hypertrophy with preserved systolic function and car-
dioprotection to massive cardiac dilatation and sudden
death.
The serine-threonine kinase, Akt (or protein kinase B), ap-
pears critically positioned between a variety of stimuli and
effectors relevant to cardiac function in normal and diseased
hearts. Akt is activated by many cardioprotective ligand-recep-
tor systems including insulin (1, 2), insulin-like growth factor-I
(3–6), gp130-dependent cytokines (7, 8), and estrogen (9).
Acute Akt activation itself protects cardiomyocytes from apop-
tosis in vitro (10) and in vivo (11, 12), while dramatically
reducing infarction and cardiac dysfunction 24 h after tran-
sient ischemia (12). However, the chronic effects of Akt activa-
tion in the heart are unknown.
In most systems, Akt activation occurs downstream of the
lipid kinase, PI 3-kinase,1 itself a powerful anti-apoptotic sig-
nal (1–8, 10). Signaling downstream of PI 3-kinase is complex
and includes mitogen-activated protein kinases and p70S6 ki-
nase, in addition to Akt, and appears to modulate many impor-
tant cell processes including cell metabolism and growth (13,
14). In Drosophila, PI 3-kinase is a critical determinant of
organ size and development (15), and recent work suggests it
plays a similar role in the mammalian heart (16). The down-
stream pathways responsible for controlling cardiomyocyte size
have not been identified.
Activation of PI 3-kinase leads to D3 phosphorylation of
membrane phosphatidylinositol 4,5-bisphosphate, generating
phosphatidylinositol 3,4,5-trisphosphate, some of which is con-
verted to phosphatidylinositol 3,4-trisphosphate by an inositol
phosphatase (17). Phosphatidylinositol 3,4-trisphosphate and
phosphatidylinositol 3,4,5-trisphosphate accumulate in the cell
membrane and recruit Akt and PDK1 to the cell membrane by
binding to their pleckstrin homology domains, leading to phos-
phorylation and activation of Akt (18). Because PDK1 is con-
stitutively active, movement of Akt to the sarcolemmal mem-
brane is sufficient to lead to its activation. For this reason,
incorporation of the src myristoylation signal creates a consti-
tutively active Akt mutant (10). Downstream substrates of Akt
mediate important effects on a broad range of cell functions
including cell survival (19–21), inflammation (22–25), and me-
tabolism (26, 27). The relative contribution of these down-
stream effectors in mediating the cardiac effects of Akt remains
undefined.
To examine the effects of chronic Akt activation in the heart,
we generated transgenic mice with cardiac overexpression of a
constitutively active mutant of Akt (myr-Akt). Mice demon-
strated a broad spectrum of phenotypes from sudden death
with massive cardiac enlargement to cardiac hypertrophy with
preserved systolic function and protection from ischemia-reper-
fusion injury. Two viable lines have been bred for five genera-
tions and characterized more fully. These lines should provide
a valuable tool for investigating the effects of Akt activation in
chronic models of cardiac disease.
EXPERIMENTAL PROCEDURES
Generation of Transgenic Mice
The cDNA encoding HA-tagged Akt with Src myristoylation (myr)
signal (kindly provided by Dr. Thomas F. Franke, Columbia University)
was subcloned downstream of the 5.5-kb murine -myosin heavy chain
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promoter (generously given by Dr. Jeffrey Robbins, Division of Molec-
ular Cardiovascular Biology, Cincinnati Children’s Hospital Research
Foundation (28)) and used to generate transgenic mice through oocyte
injection. Positive founders were identified by Southern blotting and
bred to wild-type C57BL6 mice.
Western Blotting
Hearts from 8–16-week old mice were removed from deeply anesthe-
tized animals, snap frozen, and crushed in liquid nitrogen before tissue
was homogenized in cold lysis buffer (20 mM Tris-HCl (pH 7.6), 150 mM
NaCl, 1% Triton X-100, 2 mM EGTA, 1 mM phenylmethylsulfonyl fluo-
ride, 1 mM dithiothreitol, 1 mM sodium orthovanadate, 1 g/ml leupep-
tin, 1 g/ml aprotinin). Protein concentration was measured by the
Bradford method (Bio-Rad). SDS-PAGE was performed under reducing
conditions on 12% separation gels with a 4% stacking gel. Proteins were
transferred to nitrocellulose membrane. Blots were incubated with
primary antibodies to HA (12CA5, Roche Molecular Biochemicals), Akt
(Cell Signaling), phospho-Akt (Ser-473, Cell Signaling), ERK1/2 (Santa
Cruz), phospho-ERK1/2 (Cell Signaling), GSK-3 (Transduction Lab),
phospho-GSK-3 (Cell Signaling), SAPK/JNK (Cell Signaling), p38
(Cell Signaling), phospho-p70S6 kinase (Cell Signaling), and p70S6
kinase (Cell Signaling) for 18–20 h at 4 °C. Blots were then incubated
with horseradish peroxidase-conjugated secondary antibody and signal
detected using enhanced chemiluminescence (Cell Signaling).
Kinase Assays
Akt Kinase Assay—Myocardial tissue was lysed, immunoprecipitated
with anti-Akt antibody, and used to measure Akt kinase activity using
the Akt Kinase Assay Kit (Cell Signaling) with GSK-3/ as substrate,
according to the manufacturer’s instructions.
JNK and p38 Kinase Assay—These kinase activities were measured
with the SAPK/JNK and p38 kinase Assay Kits (Cell Signaling) using
c-Jun and ATF-2 as substrates for SAPK/JNK and p38, respectively,
according to the manufacturer’s instructions.
GSK-3–Kinase activity of GSK-3 was measured as described pre-
viously (29). Briefly, frozen hearts were homogenized and lysed in the
lysis buffer. GSK-3 was immunoprecipitated with anti-GSK-3 mono-
clonal antibody coupled to protein G-Sepharose beads. After the beads
were washed, the immunoprecipitates were incubated for 20 min at
30 °C in reaction mixture containing 25 mM -glycerophosphate, 20 mM
MOPS (pH 7.2), 10 mM MgCl2, 2 mM EGTA, 0.5 M protein kinase
inhibitor, 1 mM dithiothreitol, 50 M unlabeled ATP, 5 Ci of
[-32P]ATP, and 50 M glycogen synthase peptide-2 (Upstate) as sub-
strate. The mixtures were spotted onto Whatman P81 paper, washed
with 0.5% phosphoric acid, and 32P measured by liquid scintillation
spectroscopy. Kinase activity was reduced to background levels when 10
mM LiCl was included in the reaction mixture, suggesting the activity
measured was GSK-3 (data not shown).
p70S6 Kinase Assay—Lysates were prepared as above and immuno-
precipitated with Ab to p70S6 kinase (Cell Signaling). The immobilized
immunoprecipitates were washed with HEPES-buffered saline (pH 7.5)
containing 0.1% Triton X-100 and incubated for 30 min at 25 °C in
reaction mixture containing 25 mM MOPS (pH 7.2), 12 mM MgCl2, 2 mM
EGTA, 0.5 mM dithiothreitol, 10 mM -glycerol phosphate, 0.5 M pro-
tein kinase inhibitor, 100 M unlabeled ATP, 2 Ci of [-32P]ATP, 100
M S6 synthetic peptide (RRLSSLRA; Alexis Biochemical) as substrate.
The reaction mixtures were spotted on P81 paper and washed with 0.5%
phosphoric acid. 32P incorporation into the peptide was determined by
liquid scintillation spectroscopy. For all kinase assays, samples from
8–16-week old mice were used.
Histochemical Examination
Tissues were snap-frozen in OCT medium, and 10-m sections were
prepared for hematoxylin and eosin staining. Morphological analysis of
hematoxylin and eosin-stained tissue was performed using microscopy
and a SONY imaging system.
Cardiomyocyte Isolation
Left ventricular cardiomyocytes were isolated with the perfused-
heart method described previously (30). Briefly, after deeply anesthe-
tizing the mice, hearts were quickly excised, cannulated via the aorta,
and perfused in the Langendorff mode with a constant perfusion pres-
sure of 80 mm Hg. The hearts were first perfused for 5 min at 37 °C with
1.8 mM Ca2 Tyrode (in mM: NaCl 137, KCl 5.4, CaCl2 1.8, MgCl2 0.5,
HEPES 10, and glucose 10, pH 7.4), followed by Ca2-free Tyrode for an
additional 5 min. They were then perfused with a digestion solution
containing 5 mg of collagenase D (Roche Molecular Biochemicals), 17.5
mg of collagenase B (Roche Molecular Biochemicals), and 1.5 mg of
protease XIV (Sigma) in 35 ml of Ca2-free Tyrode. After the hearts
were palpably flaccid, the digestion solution was washed out with
Ca2-free Tyrode solution for 30 s. The left ventricle (including the
septum) was cut into small pieces and gently agitated, allowing the
myocytes to be dispersed in Ca2-free Tyrode. The isolated myocytes
were then fixed with 2% paraformaldehyde for 15 min and washed with
phosphate-buffered saline. Using Cytospin2 (Shandon Inc., Pittsburgh),
FIG. 1. Overexpression of myr-Akt in the heart. A, cardiac over-
expression of HA-tagged myr-Akt. Twenty g of whole lysates from
various organs in TG20 were separated by SDS-PAGE. Transgene
expression was analyzed by Western blotting, using a monoclonal an-
tibody to the HA epitope. The transgene was expressed in the heart but
not in the lung, kidney, or skeletal muscle. Representative data from
one of three independent experiments are shown. In TG564, slight
expression of transgene was detected in the lung as well (data not
shown). B, expression pattern in female and male transgenic mice.
Immunoblotting was performed as above. Transgene expression in
TG20 females was significantly less than in TG20 males. No difference
was seen in transgene expression between female and male TG564
mice. C, Akt kinase activity. Akt kinase activity was examined with
homogenates from wild type, TG, and TG564 hearts, using the
GSK-3/ fusion protein as substrate, as described under “Experimen-
tal Procedures.” The overall level of Akt expression was significantly
increased in TG564 mice (top), as was Akt kinase activity (bottom).
Representative immunoblots of two separate experiments, total four
independent TG mice, are shown.
FIG. 2. Constitutively active Akt induces cardiac hypertrophy.
Sections obtained from hearts of 12-week-old TG and TG littermates
from the TG564 line, stained with hematoxylin and eosin, are shown.
TG heart (right) demonstrates dramatic concentric hypertrophy.
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myocytes suspended with phosphate-buffered saline were placed on
glass slides and stained with anti-HA Ab. The Ab was detected using
Vectastain ABC-Alkaline Phosphatase kit (VECTOR Lab). Images were
digitally captured, and individual cells were traced and surface areas
calculated using NIH image (version 1.60).
Echocardiography
Mice were anesthetized with ketamine (100 mg/kg intraperitoneal
injection) and the anterior chest was shaved. Cardiac ultrasound im-
aging was performed in the left lateral decubitus position using a
high-frequency 13.0 MHz liner transducer (Acuson Sequoia C256 with
a 15L8 linear array) at a frame rate of 166 frames/s and imaging depth
set at 10 mm. Estimated ejection fraction was calculated using a mod-
ified Simpson’s rule.
Ischemia-Reperfusion Model
TG20 male positive and negative littermates aged 9–12 weeks were
subjected to ischemia-reperfusion as previously described (12). Briefly,
seven animals from each group were anesthetized (Avertin), intubated,
and ventilated. Left thoracotomy was performed and LAD ligated with
7-0 silk. 5 min into ischemia, 50 l of fluorescent microspheres (10-m
FluoSpheres, Molecular Probes) were injected into the LV cavity. After
30 min, the LAD ligature was released, and reperfusion visually con-
firmed. Mice were sacrificed 24 h after ischemia. Hearts were frozen in
liquid N2, and sectioned from apex to base (Jung Frigocut 2800E, Leica)
into four 2-mm sections. To delineate the infarct, sections were incu-
bated in 5% (w/v) triphenyltetrazolium chloride (Sigma) in phosphate-
buffered saline (pH 7.4) at 37 °C for 20 min. The area-at-risk delineated
by fluorescent microspheres was visualized under UV light. For each
section, the area-at-risk and infarct area were measured from enlarged
digital micrographs using NIH image. %MI was calculated as the total
infarction area divided by the total area-at-risk for that heart.
Statistical Analysis
Data are presented as the mean  S.E. from at least three independ-
ent experiments and were compared using a two-tailed Student’s t test.
The null hypothesis was rejected at p  0.05.
RESULTS
Generation of myr-Akt Mice—Cardiac specific expression of
constitutively active Akt (myr-Akt) was driven by the murine
-myocin heavy chain promoter, which produces predomi-
nantly postnatal ventricular transgene expression (28). Three
transgene positive (TG) founders (two females, one male) died
suddenly with massive cardiac dilatation at ages 9–19 weeks.
Two viable TG lines (TG564 and TG20) were derived from
independent founders. Both lines exhibited Mendelian inherit-
ance of the transgene consistent with autosomal (TG564) and
X-linked (TG20) transmission stable over 5 generations (data
not shown). Western blotting using a monoclonal antibody to
the incorporated HA epitope confirmed cardiac-specific expres-
sion (Fig. 1A). Transgene expression was comparable in TG564
male and female mice. In TG20 mice, transgene expression was
greater in male compared with female mice (Fig. 1B). Immu-
nohistochemical staining in female TG20 mice revealed that
not all cardiomyocytes expressed the transgene (data not
shown) consistent with the expected inactivation of the trans-
gene-encoding X-chromosome in some cardiomyocytes. Immu-
noblotting with monoclonal antibody to Akt demonstrated sub-
stantial overexpression of the transgene in comparison to the
endogenous molecule (Fig. 1C). Akt activity was dramatically
increased as measured by an in vitro kinase assay using a
synthetic GSK-3/ fusion protein as substrate (Fig. 1C,
bottom).
FIG. 3. Akt activation induces cardiomyocyte hypertrophy. A,
cardiomyocyte area in TG564 mice. Isolated cardiomyocytes were
stained for the HA epitope. All cells from TG564 positive hearts ex-
pressed the transgene, while no staining was seen in transgene nega-
tive littermates. Surface area of 300 cells from two individual mice was
measured using NIH image and plotted on the graph (right). B, car-
diomyocytes from TG20 mice. Isolated cardiomyocytes from TG20 fe-
male mice demonstrated size heterogeneity. Large cells stained positive
for transgene expression while the smaller cardiomyocytes did not.
TABLE I
Heart and body weight of TG mice
n  number of animals. Data are mean  S.E.
Negative littermates (20 line) Negative littermates (564 line)
Female (n  8) Male (n  9) Female (n  9) Male (n  8)
Age (weeks) 15.0  1.2 14.5  2.4 14.1  0.7 14.5  0.5
Body weight (g) 24.7  0.9 30.4  2.4 23.4  0.9 30.4  1.7
Heart weight (mg) 111.7  3.5 128.0  3.4 102.5  4.8 130.1  0.5
HW/BW (mg/g) 4.5  0.1 4.3  0.2 4.4  0.2 4.3  0.2
TG20 positive TG564 positive
Female (n  8) Male (n  10) Female (n  10) Male (n  9)
Age (weeks) 16.7  2.3 16.6  1.0 15.8  1.7 15.4  1.3
Body weight (g) 25.1  1.5 29.5  1.9 24.5  1.3 29.6  1.7
Heart weight (mg) 175.3  11.5a 209.3  11.8a 268.1  15.9a,b 262.9  8.3a,b
HW/BW (mg/g) 7.0  0.4a 7.2  0.3a 11.0  0.4a,b 9.0  0.5a,b
a p  0.005 versus negative animals.
b p  0.005 versus the same gender in 20 line.
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Phenotypic Effects of Cardiac Akt Activation—Hearts from
transgenic mice in both lines were substantially larger than
transgene negative (TG) littermates with evident gross car-
diac hypertrophy (Fig. 2 and Table I). In TG564 mice, the
HW/BW ratio was 2.5- and 2.1-fold greater than that seen in
TG female and male littermates (p  0.005), respectively
(Table I). TG20 had less marked cardiac hypertrophy with a
HW/BW ratio 1.6- and 1.7-fold greater than that seen in TG
female and male littermates (p  0.005), respectively.
To characterize the cardiac enlargement on a cellular level,
we isolated cardiomyocytes from transgenic mice and their
littermates. Cardiomyocyte surface area was measured from
digitized micrographs of isolated cells. TG564 myocytes were
substantially larger with a mean surface area 1.7-fold greater
than that seen in TG littermates (2827 30 versus 1692 20
m2, p  0.000001) (Fig. 3A). Cardiomyocytes isolated from
TG20 females revealed significant heterogeneity in size. Im-
munohistochemical staining revealed that the larger cardiom-
yocytes expressed the Akt transgene, while the smaller car-
diomyocytes did not (Fig. 3B).
Functional Analysis—Echocardiograms were performed in
both lines from 8 to 18 weeks to assess in vivo cardiac function
as well as wall and chamber dimensions. TG20 mice demon-
strated LV hypertrophy that was slightly more marked for
male as compared with female TG mice (Table II). Wall
thickness in TG564 mice was comparably increased in both
males and females, and similar to that seen in male TG20 mice.
Systolic ventricular function (as indicated by ejection fraction)
was normal in both lines (Table II).
Signal Transduction in the myr-Akt Transgenic Mice—Sev-
eral signaling pathways relevant to cardiac hypertrophy were
examined. We observed no change in the level of total extra-
cellular regulated kinases (ERK)-1 and 2, or phosphorylated
ERK-1 and –2 (Fig. 4A). Stress-activated protein kinase
(SAPK/JNK) has also been implicated in cardiac hypertrophy
both in vitro (31) and in vivo (32). Nevertheless, there was no
difference between SAPK activity in TG and TG mice (Fig.
4B). We measured phosphorylation of p38 and p38 kinase ac-
tivity with ATF-2 as substrate. Although occasional TG mice
showed modestly enhanced phosphorylation of p38, most did
not (data not shown). Moreover, p38 activity was similar be-
tween TG and TGmice (Fig. 4C). GSK-3 is phosphorylated
and inactivated by Akt (33). GSK-3 inactivation is required
for cardiomyocyte hypertrophy in response to some stimuli in
vitro (29). However, we found no difference in total or phospho-
rylated GSK-3 between TG and TG mice (Fig. 4D, upper
panel). Similarly, there was no difference in activity (Fig. 4D,
lower panel). The ribosomal protein p70S6 kinase is another
downstream target of Akt (34), which regulates translation
initiation and has previously been reported to promote cellular
growth (35, 36) and hypertrophy (37). Phosphorylation of
Thr389 correlates well with p70S6 kinase activity (38, 39). In
Akt transgenic mice, overall expression of p70S6 kinase was
increased, as was phosphorylation at Thr389 as well as Thr421/
FIG. 4. Hypertrophic signaling pathways in Akt mice. A, ERK activation. No change in phosphorylated or total ERK1/2 was seen in
transgenic Akt mice. B, JNK activation. The activation of JNK was evaluated with using c-Jun as substrate. The activity and level of expression
of JNK were not changed. C, p38 activation. The activation of p38 was evaluated with phosphorylation of ATF-2, as described under “Experimental
Procedures.” The activity and level of expression of p38 were not changed. D, GSK-3 activation. Similarly, no change in phosphorylated (Ser9) or
total GSK-3 was seen in transgenic Akt mice (upper panel). The GSK-3 kinase activity in TG was not significantly different from that seen in
littermate controls. Cumulative data from 12 animals (6 in each group) are shown (lower panel). All blots shown are from TG564 and represent
at least three independent experiments.
TABLE II
Echocardiographic finding in TG mice
n  number of animals. Data are mean  S.E.
IVS PW EF
mm %
Female negative (n  10) 0.66  0.03 0.64  0.02 68.0  2.4a
Male negative (n  15) 0.73  0.04 0.72  0.04 65.9  1.7a
TG20 female positive (n  13) 0.82  0.03b 0.84  0.03b 63.8  1.2a
TG20 male positive (n  10) 0.96  0.04c 0.98  0.04c 62.5  2.8a
TG564 female positive (n  9) 0.97  0.04c 1.03  0.03c 62.9  1.9a
TG564 male positive (n  8) 0.94  0.05c 0.92  0.06c 62.0  2.4a
The abbreviations are: IVS, intraventricular septum; PW, posterior wall; EF, ejection fraction.
a p  not significant.
b p  0.05 versus female negative animals.
c p  0.05 versus TG20 female positive.
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Ser424 (Fig. 5, upper panel). p70S6 kinase activity was also
significantly increased in TG mice, as measured in a kinase
assay using a synthetic S6 peptide as substrate (Fig. 5, lower
panel).
Ischemia-Reperfusion Injury Model Using TG Mice—We
have demonstrated that acute Akt activation prevents ische-
mia-reperfusion injury after gene transfer (12). To examine
whether chronic Akt activation is also cardioprotective, we
measured myocardial infarction 24 h after 30 min coronary
ligation in TG20 mice (Fig. 6). The ischemic area induced by
LAD ligation (%AAR) did not differ between TG and TG
(44  3% versus 49  4, p  n.s.). However, infarct size was
reduced by50% in TG positive mice compared with littermate
controls (17  3% versus 34  4%) (Fig. 6).
DISCUSSION
In the present study, we have generated transgenic mouse
lines with overexpression of constitutively active Akt (myr-Akt)
driven by the -myocin heavy chain promoter (28). Three
founders died with massive cardiac dilatation at 9–19 weeks.
In contrast, two viable lines demonstrated gross and cellular
hypertrophy with preserved systolic function. These lines man-
ifested stable Mendelian inheritance with patterns consistent
with autosomal (TG564) and X-linked (TG20) transmission.
Myr-Akt was specifically expressed in the hearts of both lines
resulting in a dramatic increase in the activity of Akt and its
downstream substrate, p70S6 kinase.
Interest in Akt signal transduction has been heightened by
the demonstration that Akt activation reduces injury in models
of cardiac ischemia (10–12). However, all of these studies were
performed using acute viral gene transfer to achieve transient
Akt activation and documented benefits on relatively short-
term endpoints. An understanding of the effects of chronic Akt
activation both at baseline and in disease models may help
determine the value of Akt signaling as a therapeutic target. In
the current study, three transgenic founders (2F and 1M) with
cardiac transgene expression (data not shown) died suddenly
with massive cardiac enlargement at ages 9–19 weeks. While
detailed quantitative analysis of these animals was not possi-
ble, this observation raises the possibility that chronic Akt
activation can, under some circumstances, be detrimental. This
toxicity may be related to the level of expression achievable
with the -myocin heavy chain promoter. In this context, how-
ever, it is worth noting that transgenic cardiac GFP expression
has also been reported to induce dilated cardiomyopathy (40),
and thus, this phenotype must be interpreted cautiously. On
the other hand, two viable lines were produced which demon-
strated marked Akt overexpression and dramatic increases in
Akt activity that were well tolerated. Thus, while the level of
Akt expression and activation are likely to be important con-
siderations, there appears to be a broad range of Akt expression
and activation that is well tolerated by the adult mammalian
heart.
The construct used for these studies (myr-Akt) is rendered
constitutively active by initial localization to the sarcolemma.
We have previously shown that gene transfer at the same
construct recapitulates many of the signaling and biological
effects seen with insulin-like growth factor-I treatment (10).
Moreover, after Ad.myr-Akt gene transfer to the heart in vivo,
the HA-tagged construct is found not only at the sarcolemma
but also in the cytosolic fraction (data not shown). Thus, to a
large extent, myr-Akt produces a pattern of Akt activation
resembling that seen with ligand activation of the endogenous
molecule. However, the possibility that subtle differences in
subcellular localization affect downstream signaling is worthy
of further investigation.
Although PI 3-kinase activity is an important determinant of
mammalian heart size (16), the downstream substrates medi-
ating this effect have not been identified. Our data establish
that Akt activation is sufficient to cause both cellular and gross
hypertrophy and suggest that Akt may well mediate the effects
of PI 3-kinase on cardiomyocyte size. The fortuitous finding of
FIG. 5. p70S6 kinase activation. Phosphorylation of p70S6 kinase
in TG mice (upper panel). An increase in both the total (bottom) and
phosphorylated (Thr389 (top) and Thr421/Ser424 (middle)) p70S6 kinase
was seen in myr-Akt mice. p70S6 kinase activity in TG mice (lower
panel). Kinase activity was measured with phosphorylation of the syn-
thetic S6 peptide, as described under “Experimental Procedures.” The
activation of p70S6 kinase was significantly increased in TG mice.
Representative data from one of three independent experiments per-
formed in triplicate are shown.
FIG. 6. myr-Akt mice are protected from ischemia-reperfusion
injury. Micrograph, representative fluorescent microsphere distribu-
tion (bottom) and triphenyltetrazolium chloride staining (top) for 1
section from TG (left) or TG (right). Graph, %MI in TG was
reduced by50% compared with TG littermates (17 3% versus 34
4%, p  0.001). There was no change in area-at-risk (data not shown).
Cumulative data from 14 animals (7 in each group) are shown.
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X-linked transmission in TG20 mice allows us to infer that
cardiac Akt activation modulates cell size in a primary and cell
autonomous manner, rather than secondary to hemodynamic
changes or paracrine signals. The observed increase in car-
diomyocyte surface area appears to quantitatively account for
the entire increase in heart mass (assuming the increase in
mass is proportional to volume and thus surface area3/2). How-
ever, it is difficult to exclude the possibility that cardiomyocyte
hyperplasia contributes to the observed increase in cardiac
mass. Akt inhibits p21CIP1 (41, 42) and thus could affect car-
diomyocyte proliferation (43). However, we found no evidence
in bromodeoxyuridine incorporation studies for enhanced myo-
cyte proliferation, although bromodeoxyuridine incorporation
was evident in the small intestine from treated animals (data
not shown). A dominant effect of Akt on cell size rather than
number is consistent with prior work in Drosophila (44) and a
recent study of Akt expression in pancreatic islets (45).
The pathways downstream of Akt that mediate increased
cardiomyocyte size have not been fully defined in the current
study. We found no change in ERK1/2, SAPK/JNK, p38, or
GSK-3, despite a connection of these signaling pathways to
cardiac hypertrophy in other systems (29, 31, 32, 46). Recently
it has been reported that inactivation of GSK-3 by Akt induces
cardiomyocyte hypertrophy in vitro and atrial natriuretic fac-
tor expression (29, 47). Interestingly, we did not observe en-
hanced atrial natriuretic factor in the myr-Akt mice (data not
shown). In contrast, both total and phosphorylated p70S6 ki-
nase were increased, as was kinase activity. p70S6 kinase
plays an important role in cell size determination in both
mammals (35, 36) and Drosophila (48). It seems likely that the
dramatic increase in p70S6 kinase activity contributes to the
observed increase in cell size. Moreover, it is also possible that
this pathway contributes to Akt’s cytoprotective effects (49).
We have previously demonstrated that acute Akt activation
reduces infarct size after ischemia-reperfusion. However, it
was possible that chronic Akt activation would adversely affect
the heart’s response to transient ischemia. This possibility was
underscored by the observed death of 3 founders. Interestingly,
in TG20 mice, chronic Akt activation substantially reduced
infarction. Further studies will be required to identify the
downstream mediators of cardioprotection in this model and
determine whether they are the same effectors that protect the
heart after acute Akt activation (12).
In addition to providing a tool to dissect Akt mediated sig-
naling events in the heart, the mice described in this study
should help us gauge the potential of Akt activation as a ther-
apeutic target. It will be of interest to evaluate the long-term
effects of Akt activation. To date, survival and health of both
lines appear normal (data not shown). Studies in TG20 and
TG564 mice should help address these issues.
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